此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

预防心血管毒性 (PACT) 决策的患者相似性:一项可行性研究

2026年10月30日 更新者:Yee Chung Cheng、Medical College of Wisconsin

This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.

研究概览

详细说明

For this feasibility study, the researchers will create the clinical decision aid and test the central hypothesis that this novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists and will favorably impact appropriate medication use and cardiac imaging surveillance. The hypothesis is supported by preliminary data suggesting that an initial and rudimentary version of the clinical aid increases appropriate medication use and imaging follow-up in cardio-oncology patients. Success will be determined by ≥85% of clinic visits using the clinical decision aid resulting in pursuit of medication use and cardiac imaging surveillance patterns commensurate with recommendations specific to cancer survivors, with overall rates the same or higher than the group without the clinical decision aid, as well as overall favorable patient and physician focus group comments and survey responses.

研究类型

观察性的

注册 (估计的)

60

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Yee Chung Cheng, MD
  • 电话号码:414-805-4600
  • 邮箱:ycheng@mcw.edu

学习地点

    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • Froedtert & the Medical College of Wisconsin
        • 首席研究员:
          • Yee Chung Chen, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

取样方法

概率样本

研究人群

Cancer survivors at intermediate, high, or very high risk for developing cardiovascular disease will pursue a cardio-oncology visit.

描述

Inclusion Criteria:

  1. Patients ≥18 years with a history of cancer.
  2. Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
  3. Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
  4. Ability to understand a written informed consent form, and willing to sign it prior to study registration.

Exclusion Criteria:

  1. Patient <18 years.
  2. Without a personal history of cancer.
  3. Existing cardiomyopathy diagnosed after cancer diagnosis.
  4. Documented cognitive impairment.
  5. Patient or patient representative who is unable and unwilling to sign the informed consent form.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Clinical Decision Aid Group

In this group, physicians will use standard care plus the clinical decision aid.

The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.

Control Group

In this group, physicians will use standard care only.

Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Medication use
大体时间:Week 0

The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject.

Week 0
Medication use
大体时间:Week 12

The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject.

Week 12
Medication use
大体时间:Week 24

The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject.

Week 24
Imaging surveillance
大体时间:Week 0

The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject.

Week 0
Imaging surveillance
大体时间:Week 12

The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject.

Week 12
Imaging surveillance
大体时间:Week 24

The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject.

Week 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yee Chung Cheng, MD、Medical College of Wisconsin

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年12月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2022年4月29日

首先提交符合 QC 标准的

2022年5月11日

首次发布 (实际的)

2022年5月17日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月30日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅